Savara SVRA Debt-to-equity

Debt-to-equity at other companies

XER

Xeris Biopharma Holdings, Inc.XERS

19.9×—

Innoviva, Inc.INVA

0.2×—

Zevra Therapeutics, Inc.ZVRA

0×-0.5×

Upstream Bio, Inc.UPB

0×0.0×

ANI PharmaceuticalsANIP

0.5×-0.2×

PVL

Palvella TherapeuticsPVLA

0×—

FAQ

What is Savara's debt-to-equity?

Savara (SVRA) reported debt-to-equity of 0.2× in Q1 2026.

How has Savara's debt-to-equity changed year-over-year?

Savara's debt-to-equity decreased by 14.5% year-over-year, from 0.2× to 0.2×.

What is the long-term trend for Savara's debt-to-equity?

Over 5 years (2020 to 2025), Savara's debt-to-equity has grown at a -17.8% compound annual growth rate (CAGR), from 0.4× to 0.1×.

What does debt-to-equity mean?

Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.